{{Drugbox
<!--Clinical data -->
| Verifiedfields = changed
| verifiedrevid = 458271570
| tradename =  Humalog
| Drugs.com = {{drugs.com|monograph|insulin_lispro}}
| MedlinePlus = a697021
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Subcutaneous
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 133107-64-9
| ATC_prefix = A10
| ATC_suffix = AB04
| PubChem = 16132438
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00046
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = GFX7QIS1II
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04477
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=257 | H=389 | N=65 | O=77 | S=6
| molecular_weight = 5813.63 g/mol
}}
'''Insulin lispro''' (marketed by [[Eli Lilly and Company]] as '''Humalog''') is a fast acting [[insulin analog]]. It was first approved for use in the United States in 1996, making it the first insulin analog to enter the market.<ref name="NDA">{{cite web|title=Drugs@FDA:FDA Approved Products: Humalog|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020563&DrugName=HUMALOG&ActiveIngred=INSULIN%20LISPRO%20RECOMBINANT&SponsorApplicant=LILLY&ProductMktStatus=1&goto=Search.DrugDetails|publisher=U.S. Food and Drug Administration|accessdate=16 November 2012}}</ref> 

Engineered through [[recombinant DNA]] technology, the penultimate [[lysine]] and [[proline]] residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin [[protein dimer|dimer]]s and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for [[postprandial]] injections.<ref>{{cite web |url=http://www.aafp.org/afp/980115ap/noble.html |title=Insulin Lispro: A Fast-Acting Insulin Analog |accessdate=2007-06-08 |work= }}</ref>

Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a [[longer acting insulin]] (e.g. [[Insulin degludec]]) for good glycemic control.

==Medical uses==
Insulin lispro is an [[Food and Drug Administration|FDA]] approved drug used to treat people living with [[Diabetes mellitus type 1|Type 1 diabetes]] or [[Diabetes mellitus type 2|Type 2 diabetes]].<ref name=Eli2007>Product Information: HUMALOG(R) pen injection, insulin lispro (rDNA origin) pen injection. Eli Lilly and Company, Indianapolis, IN, 2007</ref> Insulin lispro has non-FDA labeled uses for [[diabetic nephropathy]] prevention, [[diabetic neuropathy]] prevention, and [[cardiovascular disease]] prevention.<ref name=Eli2007/>

==Side effects==
Common [[Side effect|side effects]] include [[Injection site reactions|skin irritation]] at the site of [[Injection (medicine)|injection]], [[hypoglycemia]], [[hypokalemia]], and [[lipodystrophy]].<ref name=Eli2007/> Other serious side effects include [[anaphylaxis]], and [[hypersensitivity]] reactions.<ref name=Eli2007/>
==Contraindications==
Do not administer insulin lispro during episodes of hypoglycemia, or if the patient has a [[hypersensitivity]] to insulin lispro or any of its [[Excipient|excipients]].<ref name=Eli2007/>

==Cost==
In the United States as of 2015 the cost is between 10.06 and 29.36 USD per 100 units.<ref>{{cite news|last1=Langreth|first1=Robert|title=Decoding Big Pharma’s Secret Drug Pricing Practices|url=https://www.bloomberg.com/graphics/2016-drug-prices/|accessdate=15 July 2016|publisher=Bloomberg|date=June 29, 2016}}</ref>

In Europe the price is far lower. The cost in the UK is between £1.66 (about $2.50) and £1.96 (about $3.00) per 100 units as of 2017.<ref>{{Cite web|url=http://www.mims.co.uk/drugs/diabetes/insulins/humalog|title=Humalog {{!}} MIMS online|website=www.mims.co.uk|access-date=2017-01-12}}</ref>

<references/>

==External links==
*[http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm200845.htm FDA Warning Letter to Lilly re: instability of Humalog Crystals-February 22, 2010]


{{Oral hypoglycemics and insulin analogs}}
{{Peptidergics}}

{{DEFAULTSORT:Insulin Lispro}}

[[Category:Eli Lilly and Company]]
[[Category:Insulin therapies]]
[[Category:Diabetes]]
[[Category:Human proteins]]
[[Category:Recombinant proteins]]
[[Category:Peptide hormones]]

[[de:Insulinpräparat#Insulin lispro]]